Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels

Lian,Zhen-Qiang; Wang,Qi; Li,Wen-Ping; Zhang,An-Qin; Wu,Ling

doi:10.3892/ijo.2012.1464

Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels

Authors:
- Zhen-Qiang Lian
- Qi Wang
- Wen-Ping Li
- An-Qin Zhang
- Ling Wu
View Affiliations

Affiliations: Breast Disease Center, Guangdong Women and Children Hospital of Guangzhou Medical College, Guangzhou 510010, P.R. China
Published online on: May 8, 2012 https://doi.org/10.3892/ijo.2012.1464
Pages: 629-638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To screen candidate methylation markers for early detection of breast cancer and to explore the relationship between methylation and gene expression, we performed methylated-CpG island recovery assay (MIRA) combined with CpG island array on 61982 CpG sites across 4162 genes in 10 cancerous and 10 non-cancerous breast tissues. Direct bisulfite sequencing and combined bisulfite restriction analysis (COBRA) were carried out in independent cancerous and non-cancerous samples. Gene expression was analyzed by microarrays and validated using RT-PCR. We detected 70 significantly hypermethylated genes in breast cancer tissues, including many novel hypermethylated genes such as ITGA4, NFIX, OTX2 and FGF12. Direct bisulfite sequencing showed widespread methylation occurring in intragenic regions of the WT1, PAX6 and ITGA4 genes and in the promoter region of the OTX2 gene in breast cancer tissues. COBRA assay confirmed that the WT1, OTX2 and PAX6 genes were hypermethylated in breast cancer tissues. Clustering analysis of the gene expression of 70 significantly hypermethylated genes revealed that most hypermethylated genes in breast cancer were not expressed in breast tissues. RT-PCR assay confirmed that WT1 and PITX2 were only weakly expressed in the breast cancer tissues and were not expressed in most non-cancerous breast tissues. OTX2 and PAX6 were not expressed in either breast cancer or non-cancerous tissues. In conclusion, these results will expand our knowledge of hypermethylated genes and methylation sites for early detection of breast cancer and deepen our understanding of the relationship between methylation and gene expression. The MIRA approach can screen candidate methylated genes for further clinical validation more effectively than gene expression microarray-based strategy.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar
3	Martens JW, Margossian AL, Schmitt M, Foekens J and Harbeck N: DNA methylation as a biomarker in breast cancer. Future Oncol. 5:1245–1256. 2009. View Article : Google Scholar : PubMed/NCBI
4	Jovanovic J, Ronneberg JA, Tost J and Kristensen V: The epigenetics of breast cancer. Mol Oncol. 4:242–254. 2010. View Article : Google Scholar : PubMed/NCBI
5	Brooks J, Cairns P and Zeleniuch-Jacquotte A: Promoter methylation and the detection of breast cancer. Cancer Causes Control. 20:1539–1550. 2009. View Article : Google Scholar : PubMed/NCBI
6	Sproul D, Nestor C, Culley J, et al: Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci USA. 108:4364–4369. 2011. View Article : Google Scholar
7	Ngan CY, Yamamoto H, Seshimo I, et al: Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer. 96:986–992. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chen WD, Han ZJ, Skoletsky J, et al: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 97:1124–1132. 2005. View Article : Google Scholar : PubMed/NCBI
9	Ruike Y, Imanaka Y, Sato F, Shimizu K and Tsujimoto G: Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics. 11:1372010. View Article : Google Scholar
10	Wu X, Rauch TA, Zhong X, et al: CpG island hypermethylation in human astrocytomas. Cancer Res. 70:2718–2727. 2010. View Article : Google Scholar : PubMed/NCBI
11	Tommasi S, Karm DL, Wu X, Yen Y and Pfeifer GP: Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res. 11:R142009. View Article : Google Scholar : PubMed/NCBI
12	Rauch TA and Pfeifer GP: The MIRA method for DNA methylation analysis. Methods Mol Biol. 507:65–75. 2009. View Article : Google Scholar : PubMed/NCBI
13	Richards AA, Santos LJ, Nichols HA, et al: Cryptic chromosomal abnormalities identified in children with congenital heart disease. Pediatr Res. 64:358–363. 2008. View Article : Google Scholar : PubMed/NCBI
14	Leung TY, Vogel I, Lau TK, et al: Identification of submicroscopic chromosomal aberrations in fetuses with increased nuchal translucency and apparently normal karyotype. Ultrasound Obstet Gynecol. 38:314–319. 2011. View Article : Google Scholar : PubMed/NCBI
15	Xiong Z and Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25:2532–2534. 1997. View Article : Google Scholar : PubMed/NCBI
16	Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, et al: IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene. 29:1681–1690. 2010.PubMed/NCBI
17	Rauch T, Wang Z, Zhang X, et al: Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA. 104:5527–5532. 2007. View Article : Google Scholar : PubMed/NCBI
18	Maier S, Nimmrich I, Koenig T, et al: DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer. 43:1679–1686. 2007.PubMed/NCBI
19	Harbeck N, Nimmrich I, Hartmann A, et al: Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol. 26:5036–5042. 2008. View Article : Google Scholar
20	Loeb DM, Evron E, Patel CB, et al: Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 61:921–925. 2001.
21	Yang JL, Klinkebiel D, Boland MJ, Tang L and Christman JK: [Promoter methylation and mRNA expression of WT1 gene in MCF10 breast cancer model]. Zhonghua Bing Li Xue Za Zhi. 36:253–258. 2007.(In Chinese).
22	Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr and Daniel CW: Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA. 94:8132–8137. 1997. View Article : Google Scholar : PubMed/NCBI
23	Laux DE, Curran EM, Welshons WV, Lubahn DB and Huang TH: Hypermethylation of the Wilms’ tumor suppressor gene CpG island in human breast carcinomas. Breast Cancer Res Treat. 56:35–43. 1999.
24	Brenet F, Moh M, Funk P, et al: DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One. 6:e145242011. View Article : Google Scholar : PubMed/NCBI